期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型白蛋白溶剂型纳米紫杉醇治疗乳腺癌研究进展 被引量：6

Novel albumin-bound nanoparticle paclitaxel for breast cancer
原文传递
导出
摘要 Capxol是一种新型白蛋白溶剂型纳米紫杉醇,已完成的临床Ⅰ、Ⅱ、Ⅲ期试验显示, Capxol治疗转移性乳腺癌较传统紫杉类药物有着更好的疗效,其治疗相关的剂量限制性毒性主要为骨髓抑制、外周感觉神经炎。 Capxol is a novel nanoparticle, albumin-bound paclitaxel, the phase Ⅰ to Ⅲ clinical trails was performed to demonstrate superior efficacy and reduced toxicity of Capxol compared with standard paclitaxel, the dose-limiting toxicities related to the treatment with Capxol are neutropenia and peripheral neuritis.
作者 王凯 吴世凯 宋三泰
机构地区 军事医学科学院附属医院乳腺癌内科
出处 《国际肿瘤学杂志》 CAS 2006年第9期678-680,共3页 Journal of International Oncology
关键词 乳腺肿瘤 药物疗法 毒性 Breast neoplasms Drug therapy Toxicity
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Crown J, O'Leary M. The taxanes : An update. Lancet, 2000, 355(9210) :1176-1178.
  • 2Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med,2005,352(22) :2302-2313.
  • 3Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer,2001,37(13) :1590-1598.
  • 4Weiss RB, Donehower RC, Wiemik PH, et al. Hypersensitivity reactions from Taxol. J C lin Oncol, 1990,8 (7) :1263-1268.
  • 5Gradishar WJ, Tjulandin S, Davidson N, et al. Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol , 2005,23(31):7794-7803.
  • 6Ten Tije A J, Verweij J, Loos W J, et al. Pharmacological effects of formulation vehicles:Implications for cancer chemotherapy. Clin Pharmacokinet, 2003,42 ( 7 ) : 665 - 685.
  • 7Porter PL, Sage EH, Lane TF, et al. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem, 1995,43 ( 8 ) :791 -800.
  • 8Kim YW,Park YK,Lee J,et al. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci,1998,13(6) :652-657.
  • 9Rempel SA, Ge S, Gutierrez JA. SPARC : A potential diagnostic marker of invasive meningiomas. Clin Cancer Res, 1999,5 (2) :237-241.
  • 10Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC,gp60, and microvascular endothelium. Am J Physiol , 1992,263 (6 Pt 2) :H1872-H1879.

二级参考文献22

  • 1[1]Taxol(R) (paclitaxel) Injection [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Co; March 2003
  • 2[2]Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent [ J]. Agents Actions, 1977, 7 ( 1 ): 63 -67.
  • 3[3]Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation [J]. Eur J Cancer, 2001, 37(13): 1590 - 1598.
  • 4[4]Rowinsky EK, Donehower RC. Paclitaxel (taxol) [J]. N Engl J Med, 1995, 332(15): 1004 - 1014.
  • 5[5]Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: an in vitro study [J]. J Natl Cancer Inst, 1998, 90(4):300 - 305.
  • 6[6]ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy [J] .Clin Pharmacokinet, 2003, 42 (7): 665 - 685.
  • 7[7]van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles [J]. Cancer Chemother Pharmacol, 2001, 47(4): 309 - 318.
  • 8[8]Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications [J] . Cancer Res, 1999, 59(7): 1454 - 1457.
  • 9[9]Ibrahim NK, Desai N, Legha S, et al. Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free proteinstabilized. nanoparticle formulation of paclitaxel [J]. Clin Cancer Res, 2002, 8(5): 1038 - 1044.
  • 10[10]Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over [J]. J Clin Oncol, 2000, 18(4): 724 - 733.

共引文献38

同被引文献34

引证文献6

二级引证文献29

国际肿瘤学杂志
2006年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部